Peroxiredoxin 5 overexpression enhances tumorigenicity and correlates with poor prognosis in gastric cancer

  • Authors:
    • Bokyung Kim
    • Yeon Soo Kim
    • Hye-Mi Ahn
    • Hyo Jin Lee
    • Min Kyu Jung
    • Hyun Yong Jeong
    • Dong Kyu Choi
    • Jun Hyeog Lee
    • Sang-Rae Lee
    • Jin Man Kim
    • Dong-Seok Lee
  • View Affiliations

  • Published online on: May 19, 2017     https://doi.org/10.3892/ijo.2017.4013
  • Pages: 298-306
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gastric cancer is one of the leading causes of cancer-related deaths worldwide. Despite the advanced surgical resection techniques and anticancer drugs currently available to treat early stage gastric cancer, the prognosis of patients with gastric cancer remains poor. The epithelial to mesenchymal transition (EMT) is an important process for the initiation of tumorigenesis. Recent studies suggested that reactive oxygen species (ROS) can promote cell migration and invasion. Thus, an imbalance of redox homeostasis can result in cancer cells exhibiting EMT properties. PRXs are upregulated in various tumors in the breast, bladder, lung, cervical, ovarian, prostate, esophageal, and hepatocellular. However, PRX expression and its impact on disease prognosis, patient survival rate, and EMT are rarely studied in the context of human gastric cancer. The expression of PRX5 was significantly correlated with tumor size, depth of tumor, lymphatic invasion in patients of gastric cancer. In addition, overexpression of PRX5 enhanced carcinogenicity by increasing the proliferation and invasiveness of gastric cancer cells via upregulation of Snail. Taken together, we suggest that PRX5 may be a potential factor that may contribute to poor prognosis of gastric cancer through enhancing the mesenchymal phenotype. Finally, PRX5 is a putative therapeutic target and clinical strategy for various cancers overexpressing PRX5.
View Figures
View References

Related Articles

Journal Cover

July-2017
Volume 51 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kim B, Kim YS, Ahn H, Lee HJ, Jung MK, Jeong HY, Choi DK, Lee JH, Lee S, Kim JM, Kim JM, et al: Peroxiredoxin 5 overexpression enhances tumorigenicity and correlates with poor prognosis in gastric cancer. Int J Oncol 51: 298-306, 2017
APA
Kim, B., Kim, Y.S., Ahn, H., Lee, H.J., Jung, M.K., Jeong, H.Y. ... Lee, D. (2017). Peroxiredoxin 5 overexpression enhances tumorigenicity and correlates with poor prognosis in gastric cancer. International Journal of Oncology, 51, 298-306. https://doi.org/10.3892/ijo.2017.4013
MLA
Kim, B., Kim, Y. S., Ahn, H., Lee, H. J., Jung, M. K., Jeong, H. Y., Choi, D. K., Lee, J. H., Lee, S., Kim, J. M., Lee, D."Peroxiredoxin 5 overexpression enhances tumorigenicity and correlates with poor prognosis in gastric cancer". International Journal of Oncology 51.1 (2017): 298-306.
Chicago
Kim, B., Kim, Y. S., Ahn, H., Lee, H. J., Jung, M. K., Jeong, H. Y., Choi, D. K., Lee, J. H., Lee, S., Kim, J. M., Lee, D."Peroxiredoxin 5 overexpression enhances tumorigenicity and correlates with poor prognosis in gastric cancer". International Journal of Oncology 51, no. 1 (2017): 298-306. https://doi.org/10.3892/ijo.2017.4013